

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|--|---------------|------|--------|------------------|------------------|------------------------------------|-----------------|------------------|-----|------|------------------|------------------------------------|------------------|-------|-----------------|------------------|------|------|------------------|------------------|------------------|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (121) Total T3 | | | | | | | 77 | 72 | 94% | | | | | | | 81 | 65 | 80% | | | | | |
| Samples and groups [nmol/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 6,27 | 0,59 | 9,5 | 81 | | | | | | 77 | 75 | 97% | CRV | 6,4 | 0,085 | 20% | 5,12 | 7,68 | 81 | 74 | 91% | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 6,28 | 0,00 | 0,12 | 5 | 0 | CVPG | 6,28 | 0,021 | 15% | 5,33 | 7,23 | | | | | | | | 5 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 5,89 | 0,51 | 8,7 | 24 | 0 | CVPG | 5,88 | 0,22 | 15% | 4,99 | 6,77 | | | | | | | | 24 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 6,23 | 0,42 | 6,7 | 12 | 0 | CVPG | 6,41 | 0,39 | 15% | 5,44 | 7,38 | | | | | | | | 12 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 4,72 | 0,33 | 6,9 | 6 | 0 | CVPG | 4,96 | 0,25 | 15% | 4,21 | 5,71 | | | | | | | | 6 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 6,55 | 0,27 | 4,1 | 16 | 0 | CVPG | 6,72 | 0,099 | 15% | 5,71 | 7,73 | | | | | | | | 16 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 6,83 | 0,34 | 5,0 | 14 | 0 | CVPG | 6,94 | 0,17 | 15% | 5,89 | 7,99 | | | | | | | | 14 | | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | 1x 2/25, 1x 3/15, 1x 4/40, 1x 6/60 | | | | | | 1x 2/25, 1x 3/15, 1x 4/40, 1x 6/60 | | | | | | | | | | |
| Sample B | | 1,91 | 0,30 | 16 | 81 | | | | | | 77 | 74 | 96% | CRV | 2,049 | 0,020 | 20% | 1,63 | 2,46 | 81 | 67 | 83% | |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 1,98 | 0,03 | 1,5 | 5 | 0 | CVPG | 1,98 | 0,084 | 15% | 1,68 | 2,28 | | | | | | | | 5 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 1,68 | 0,08 | 5,3 | 24 | 0 | CVPG | 1,68 | 0,038 | 15% | 1,42 | 1,94 | | | | | | | | 24 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 1,74 | 0,17 | 9,6 | 12 | 0 | CVPG | 1,77 | 0,097 | 15% | 1,5 | 2,04 | | | | | | | | 12 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 1,47 | 0,10 | 7,1 | 6 | 0 | CVPG | 1,53 | 0,14 | 15% | 1,3 | 1,76 | | | | | | | | 6 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 2,15 | 0,08 | 4,0 | 16 | 0 | CVPG | 2,21 | 0,034 | 15% | 1,87 | 2,55 | | | | | | | | 16 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 2,21 | 0,08 | 3,6 | 14 | 0 | CVPG | 2,3 | 0,083 | 15% | 1,95 | 2,65 | | | | | | | | 14 | | | |
| Other | | | | | 4 | 0 | | | | | | | | | | | | | | | 4 | | |
| | | | | | | | 1x 2/25, 1x 3/15, 1x 4/40, 1x 6/60 | | | | | | 1x 2/25, 1x 3/15, 1x 4/40, 1x 6/60 | | | | | | | | | | |
| (122) Total T4 | | | | | | | 66 | 61 | 92% | | | | | | | 73 | 71 | 97% | | | | | |
| Samples and groups [nmol/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 199 | 13 | 6,4 | 73 | | | | | | 66 | 64 | 97% | CRV | 201,3 | 2,3 | 17% | 167 | 236 | 73 | 72 | 99% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 199 | 9,8 | 4,9 | 25 | 0 | CVPG | 198 | 4,1 | 13% | 172 | 224 | | | | | | | | 25 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 192 | 12 | 6,4 | 10 | 0 | CVPG | 192 | 7,9 | 13% | 167 | 217 | | | | | | | | 10 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 208 | 11 | 5,4 | 6 | 0 | CVPG | 212 | 6,8 | 13% | 184 | 240 | | | | | | | | 6 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 196 | 13 | 6,6 | 13 | 0 | CVPG | 192 | 4,6 | 13% | 167 | 217 | | | | | | | | 13 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 208 | 9,2 | 4,4 | 12 | 0 | CVPG | 209 | 5,8 | 13% | 181 | 237 | | | | | | | | 12 | | | |
| Other | | | | | 7 | 0 | | | | | | | | | | | | | | | 7 | | |
| | | | | | | | 1x 2/25, 1x 3/15, 4x 3/25, 1x 4/40 | | | | | | 1x 2/25, 1x 3/15, 4x 3/25, 1x 4/40 | | | | | | | | | | |
| Sample B | | 255 | 25 | 9,7 | 73 | | | | | | 66 | 62 | 94% | CRV | 261,2 | 2,9 | 17% | 216 | 306 | 73 | 71 | 97% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 271 | 14 | 5,0 | 25 | 1 | CVPG | 269 | 6,5 | 13% | 234 | 304 | | | | | | | | 25 | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|----------|---------------|----|--------|------------------|------------------|--------------|-----------------|------------------|-----|-----|------------------|------------------|------------------|-----|-----------------|------------------|-----|-----|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (122) Total T4 | | | | | 73 | | | | | | | 66 | 61 | 92% | | | | | | | 73 | 71 | 97% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 255 | 25 | 9,7 | 73 | | | | | | | 66 | 62 | 94% | CRV | 261,2 | 2,9 | 17% | 216 | 306 | 73 | 71 | 97% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 228 | 11 | 5,0 | 10 | 0 | CVPG | 230 | 7,3 | 13% | 200 | 260 | 10 | | | | | | | | 10 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 239 | 27 | 11 | 6 | 0 | CVPG | 239 | 11 | 13% | 207 | 271 | 6 | | | | | | | | 6 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 255 | 19 | 7,3 | 13 | 0 | CVPG | 251 | 6,4 | 13% | 218 | 284 | 13 | | | | | | | | 13 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 268 | 13 | 4,7 | 12 | 0 | CVPG | 267 | 7,7 | 13% | 232 | 302 | 12 | | | | | | | | 12 | | |
| Other | | | | | 7 | 0 | | | | | | | 0 | | | | | | | | 7 | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-------------------------------------|------------------|-----|------|------------------|------------------|------------------|------|-----------------|------------------|----|----|------------------|------------------|------------------|---|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (124) Free T4 | | | | | 196 | | | | | | | | 194 | 181 | 93% | | | | | | | | 0 |
| Samples and groups | [pmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 40,1 | 8,0 | 20 | 196 | | | | | | | | 194 | 186 | 96% | | | | | | | | 0 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 39,2 | 1,7 | 4,4 | 28 | 0 | CVPG | 39,6 | 0,42 | 13% | 34,4 | 44,8 | 28 | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | 2 | | | | | | | | | | |
| | | | | | | | | 1x 2/25, 1x 3/60, 1x 4/40, 1x 4/149 | | | | | | | | | | | | | | | |
| Sample B | | 52,0 | 12 | 24 | 196 | | | | | | | | 194 | 185 | 95% | | | | | | | | 0 |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 54,0 | 3,9 | 7,2 | 8 | 0 | CVPG | 55,5 | 1,7 | 13% | 48,2 | 62,8 | 8 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 38,5 | 3,0 | 7,7 | 62 | 0 | CVPG | 38,2 | 0,53 | 13% | 33,2 | 43,2 | 62 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 51,1 | 3,3 | 6,4 | 30 | 0 | CVPG | 50,8 | 0,69 | 13% | 44,1 | 57,5 | 30 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | | 60,6 | 2,9 | 4,7 | 12 | 0 | CVPG | 62,6 | 0,89 | 13% | 54,4 | 70,8 | 12 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 64,9 | 3,9 | 6,0 | 52 | 0 | CVPG | 65 | 0,38 | 13% | 56,5 | 73,5 | 52 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 52,8 | 2,5 | 4,7 | 28 | 0 | CVPG | 53,5 | 0,64 | 13% | 46,5 | 60,5 | 28 | | | | | | | | | | |
| Other | | | | | 4 | 0 | | | | | | | 2 | | | | | | | | | | |
| | | | | | | | | 1x 2/25, 1x 3/60, 1x 4/40, 1x 4/149 | | | | | | | | | | | | | | | |
| (125) Free T3 | | | | | 149 | | | | | | | | 149 | 139 | 93% | | | | | | | | 0 |
| Samples and groups | [pmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 24,2 | 4,3 | 18 | 149 | | | | | | | | 149 | 145 | 97% | | | | | | | | 0 |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 23,8 | 0,12 | 0,50 | 5 | 0 | CVPG | 24 | 1,1 | 15% | 20,4 | 27,6 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 23,6 | 1,7 | 7,4 | 50 | 0 | CVPG | 23,9 | 0,32 | 15% | 20,3 | 27,5 | 50 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 20,2 | 1,5 | 7,2 | 21 | 0 | CVPG | 20,2 | 0,27 | 15% | 17,1 | 23,3 | 21 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | | 18,2 | 1,4 | 7,8 | 6 | 0 | CVPG | 18,3 | 0,28 | 15% | 15,5 | 21,1 | 6 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 29,4 | 0,91 | 3,1 | 39 | 0 | CVPG | 29,5 | 0,087 | 15% | 25 | 34 | 39 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 21,4 | 0,92 | 4,3 | 25 | 0 | CVPG | 21 | 0,23 | 15% | 17,8 | 24,2 | 25 | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | |
| | | | | | | | | 1x 3/15, 1x 4/40, 1x 4/149 | | | | | | | | | | | | | | | |
| Sample B | | 6,97 | 1,1 | 16 | 149 | | | | | | | | 149 | 143 | 96% | | | | | | | | 0 |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 6,83 | 0,36 | 5,2 | 5 | 0 | CVPG | 6,95 | 0,36 | 15% | 5,9 | 8 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 5,99 | 0,55 | 9,3 | 50 | 0 | CVPG | 6,16 | 0,084 | 15% | 5,23 | 7,09 | 50 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 6,24 | 0,40 | 6,3 | 21 | 0 | CVPG | 6,25 | 0,083 | 15% | 5,31 | 7,19 | 21 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulite) | | 8,30 | 1,0 | 13 | 6 | 0 | CVPG | 7,82 | 0,22 | 15% | 6,64 | 9 | 6 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 7,68 | 0,39 | 5,0 | 39 | 0 | CVPG | 7,61 | 0,030 | 15% | 6,46 | 8,76 | 39 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 8,06 | 0,28 | 3,5 | 25 | 0 | CVPG | 7,95 | 0,071 | 15% | 6,75 | 9,15 | 25 | | | | | | | | | | |
| Other | | | | | 3 | 0 | | | | | | | 3 | | | | | | | | | | |
| | | | | | | | | 1x 3/15, 1x 4/40, 1x 4/149 | | | | | | | | | | | | | | | |
| (200) Ferritin | | | | | 131 | | | | | | | | 128 | 113 | 88% | | | | | | | | 0 |
| Samples and groups | [µg/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 110 | 20 | 18 | 131 | | | | | | | | 128 | 128 | 100% | | | | | | | | 0 |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | | |
|--|----------|---------------|-----|--------|------------------|------------------|--------------|---|------------------|-----|------|------------------|------------------|------------------|-------|-----------------|------------------|-----|------|------------------|------------------|------------------|-----|--|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | | |
| (200) Ferritin | | | | | 131 | | | | | | | 128 | 113 | 88% | | | | | | | 0 | | | |
| Samples and groups | [µg/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 110 | 20 | 18 | 131 | | | | | | | 128 | 128 | 100% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 130 | 7,6 | 5,8 | 32 | 0 | CVPG | 132 | 2,0 | 24% | 100 | 164 | 32 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 81,6 | 4,3 | 5,3 | 19 | 0 | CVPG | 83,9 | 1,6 | 24% | 63,7 | 105 | 19 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 99,2 | 10 | 10 | 7 | 0 | CVPG | 103 | 3,6 | 24% | 78,2 | 128 | 7 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 119 | 11 | 9,1 | 23 | 0 | CVPG | 120 | 1,2 | 24% | 91,2 | 149 | 23 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 105 | 6,7 | 6,4 | 20 | 0 | CVPG | 105 | 2,0 | 24% | 79,8 | 131 | 20 | | | | | | | | | | | |
| (6) IMT, IMN; (58) Beckman Coulter (AU) | | 99,5 | 5,2 | 5,2 | 7 | 0 | CVPG | 99,9 | 2,7 | 24% | 75,9 | 124 | 7 | | | | | | | | | | | |
| (6) IMT, IMN; (60) Roche | | 117 | 7,0 | 6,0 | 13 | 0 | CVPG | 120 | 2,1 | 24% | 91,2 | 149 | 13 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | | 1x 3/15, 4x 3/25, 1x 4/40, 1x 4/149, 3x 6/1 | | | | | | | | | | | | | | | | |
| Sample B | | 17,3 | 4,6 | 27 | 131 | | | | | | | 128 | 113 | 88% | | | | | | | 0 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 14,1 | 2,6 | 19 | 32 | 0 | CVPG | 15,3 | 0,67 | 24% | 11,6 | 19 | 32 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 14,0 | 1,7 | 12 | 19 | 0 | CVPG | 14,2 | 0,58 | 24% | 10,7 | 17,7 | 19 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin) | | 15,6 | 3,5 | 22 | 7 | 0 | CVPG | 17,7 | 1,3 | 24% | 13,4 | 22 | 7 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 22,7 | 2,9 | 13 | 23 | 0 | CVPG | 22,9 | 0,44 | 24% | 17,4 | 28,4 | 23 | | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 16,2 | 2,8 | 17 | 20 | 0 | CVPG | 16,5 | 0,63 | 24% | 12,5 | 20,5 | 20 | | | | | | | | | | | |
| (6) IMT, IMN; (58) Beckman Coulter (AU) | | 17,5 | 2,8 | 16 | 7 | 0 | CVPG | 17,5 | 1,2 | 24% | 13,3 | 21,7 | 7 | | | | | | | | | | | |
| (6) IMT, IMN; (60) Roche | | 23,3 | 4,8 | 21 | 13 | 0 | CVPG | 25 | 0,66 | 24% | 19 | 31 | 13 | | | | | | | | | | | |
| Other | | | | | 10 | 0 | | | | | | | 7 | | | | | | | | | | | |
| | | | | | | | | 1x 3/15, 4x 3/25, 1x 4/40, 1x 4/149, 3x 6/1 | | | | | | | | | | | | | | | | |
| (301) Cortisol | | | | | 97 | | | | | | | 93 | 87 | 94% | | | | | | | 97 | 86 | 89% | |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1010 | 120 | 12 | 97 | | | | | | | 93 | 90 | 97% CRV | 1029 | 11 | 22% | 802 | 1260 | | 97 | 95 | 98% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 891 | 58 | 6,5 | 29 | 0 | CVPG | 908 | 14 | 16% | 762 | 1060 | 29 | | | | | | | | 29 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 1030 | 71 | 6,9 | 12 | 0 | CVPG | 1000 | 27 | 16% | 840 | 1160 | 12 | | | | | | | | 12 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 1060 | 95 | 9,0 | 34 | 0 | CVPG | 1040 | 12 | 16% | 873 | 1210 | 34 | | | | | | | | 34 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 1130 | 55 | 4,9 | 14 | 0 | CVPG | 1140 | 19 | 16% | 957 | 1330 | 14 | | | | | | | | 14 | | | |
| Other | | | | | 8 | 0 | | | | | | | 4 | | | | | | | | | 8 | | |
| | | | | | | | | 3x 3/25, 4x 4/29, 1x 4/164 | | | | | | | | | | | | | | | | |
| Sample B | | 286 | 37 | 13 | 97 | | | | | | | 93 | 89 | 96% CRV | 305,9 | 3,7 | 22% | 238 | 374 | | 97 | 87 | 90% | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 259 | 18 | 7,1 | 29 | 0 | CVPG | 263 | 4,0 | 16% | 220 | 306 | 29 | | | | | | | | 29 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 250 | 20 | 8,2 | 12 | 0 | CVPG | 247 | 6,4 | 16% | 207 | 287 | 12 | | | | | | | | 12 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 308 | 22 | 7,1 | 34 | 0 | CVPG | 303 | 2,6 | 16% | 254 | 352 | 34 | | | | | | | | 34 | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 315 | 9,2 | 2,9 | 14 | 0 | CVPG | 309 | 5,7 | 16% | 259 | 359 | 14 | | | | | | | | 14 | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|--|----------|---------------|------|--------|------------------|------------------|---------------------------------------|-----------------|------------------|-----|-------|------------------|------------------|------------------|-----|-----------------|------------------|----------------------------|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (301) Cortisol | [nmol/L] | | | | 97 | | | | | | | 93 | 87 | 94% | | | | | | | 97 | 86 | 89% |
| --- Samples and groups --- | | | | | | | | | | | | | | | | | | | | | | | |
| Sample B | | 286 | 37 | 13 | 97 | | | | | | | 93 | 89 | 96% | CRV | 305,9 | 3,7 | 22% | 238 | 374 | 97 | 87 | 90% |
| Other | | | | | 8 | 0 | | | | | | 4 | | | | | | | | | 8 | | |
| | | | | | | | 3x 3/25, 4x 4/29, 1x 4/164 | | | | | | | | | | | 3x 3/25, 4x 4/29, 1x 4/164 | | | | | |
| (302) 17-beta-estradiol | [pmol/L] | | | | 95 | | | | | | | 94 | 92 | 98% | | | | | | | 0 | | |
| --- Samples and groups --- | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 658 | 43 | 6,5 | 95 | | | | | | | 94 | 92 | 98% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 655 | 51 | 7,8 | 29 | 0 | CVPG | 664 | 9,2 | 22% | 517 | 811 | 29 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 665 | 39 | 5,9 | 13 | 0 | CVPG | 669 | 10 | 22% | 521 | 817 | 13 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 667 | 32 | 4,8 | 30 | 0 | CVPG | 670 | 4,9 | 22% | 522 | 818 | 30 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 648 | 45 | 7,0 | 14 | 0 | CVPG | 653 | 10,0 | 22% | 509 | 797 | 14 | | | | | | | | | | |
| Other | | | | | 9 | 0 | | | | | | | 8 | | | | | | | | | | |
| | | | | | | | 1x 2/25, 4x 3/25, 4x 4/29 | | | | | | | | | | | | | | | | |
| Sample B | | 1370 | 160 | 12 | 95 | | | | | | | 94 | 94 | 100% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 1240 | 78 | 6,3 | 29 | 0 | CVPG | 1250 | 14 | 22% | 975 | 1530 | 29 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 1520 | 110 | 7,1 | 13 | 0 | CVPG | 1520 | 22 | 22% | 1180 | 1860 | 13 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 1480 | 68 | 4,6 | 30 | 0 | CVPG | 1490 | 9,6 | 22% | 1160 | 1820 | 30 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 1350 | 120 | 8,7 | 14 | 0 | CVPG | 1340 | 18 | 22% | 1040 | 1640 | 14 | | | | | | | | | | |
| Other | | | | | 9 | 0 | | | | | | | 8 | | | | | | | | | | |
| | | | | | | | 1x 2/25, 4x 3/25, 4x 4/29 | | | | | | | | | | | | | | | | |
| (303) Aldosterone | [nmol/L] | | | | 21 | | | | | | | 18 | 18 | 100% | | | | | | | 0 | | |
| --- Samples and groups --- | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 1,21 | 0,35 | 29 | 21 | | | | | | | 18 | 18 | 100% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | | 1,07 | 0,10 | 9,6 | 10 | 0 | CVPG | 1,13 | 0,021 | 33% | 0,757 | 1,51 | 10 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | | 1,61 | 0,03 | 2,3 | 6 | 0 | CVPG | 1,63 | 0,029 | 33% | 1,09 | 2,17 | 6 | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 2 | | | | | | | | | | |
| | | | | | | | 1x 1/185, 2x 1/218, 1x 2/66, 1x 4/999 | | | | | | | | | | | | | | | | |
| Sample B | | 1,49 | 0,30 | 20 | 21 | | | | | | | 18 | 18 | 100% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin | | 1,40 | 0,13 | 9,0 | 10 | 0 | CVPG | 1,46 | 0,028 | 33% | 0,978 | 1,95 | 10 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | | 1,78 | 0,08 | 5,0 | 6 | 0 | CVPG | 1,73 | 0,024 | 33% | 1,15 | 2,31 | 6 | | | | | | | | | | |
| Other | | | | | 5 | 0 | | | | | | | 2 | | | | | | | | | | |
| | | | | | | | 1x 1/185, 2x 1/218, 1x 2/66, 1x 4/999 | | | | | | | | | | | | | | | | |
| (304) Progesterone | [nmol/L] | | | | 91 | | | | | | | 90 | 88 | 98% | | | | | | | 91 | 79 | 87% |
| --- Samples and groups --- | | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 26,9 | 5,2 | 19 | 91 | | | | | | | 90 | 89 | 99% | CRV | 26,35 | 0,26 | 26% | 19,4 | 33,3 | 91 | 79 | 87% |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 35,4 | 1,7 | 4,9 | 6 | 0 | CVPG | 35,4 | 0,98 | 20% | 28,3 | 42,5 | 6 | | | | | | | | | | 6 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 26,8 | 1,9 | 6,9 | 30 | 0 | CVPG | 26,3 | 0,42 | 20% | 21 | 31,6 | 30 | | | | | | | | | | 30 |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 22,6 | 2,6 | 12 | 11 | 0 | CVPG | 22,3 | 0,54 | 20% | 17,8 | 26,8 | 11 | | | | | | | | | | 11 |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|-----|------|------------------|------------------|------------------|---------------------------|-----------------|------------------|-----|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (304) Progesterone | | | | | 91 | | | | | | | 90 | 88 | 98% | | | | | | | 91 | 79 | 87% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 26,9 | 5,2 | 19 | 91 | | | | | | | 90 | 89 | 99% | CRV | 26,35 | 0,26 | 26% | 19,4 | 33,3 | 91 | 79 | 87% |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immolute) | | 21,2 | 0,74 | 3,5 | 5 | 0 | CVPG | 21,9 | 0,45 | 20% | 17,5 | 26,3 | 5 | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 30,9 | 1,4 | 4,6 | 26 | 0 | CVPG | 31 | 0,23 | 20% | 24,8 | 37,2 | 26 | | | | | | | | 26 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 20,3 | 1,4 | 7,0 | 12 | 0 | CVPG | 21 | 0,45 | 20% | 16,8 | 25,2 | 12 | | | | | | | | 12 | | |
| Other | | | | | 1 | 0 | | | | | | | 0 | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2/25 | | | | | | | | |
| Sample B | | 12,3 | 1,7 | 14 | 91 | | | | | | | 90 | 88 | 98% | CRV | 12,23 | 0,13 | 26% | 9,05 | 15,5 | 91 | 88 | 97% |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 15,1 | 0,75 | 5,0 | 6 | 0 | CVPG | 15,6 | 0,66 | 20% | 12,4 | 18,8 | 6 | | | | | | | | 6 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 11,8 | 0,72 | 6,1 | 30 | 0 | CVPG | 11,7 | 0,15 | 20% | 9,36 | 14,1 | 30 | | | | | | | | 30 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 10,9 | 1,4 | 13 | 11 | 0 | CVPG | 10,8 | 0,34 | 20% | 8,64 | 13 | 11 | | | | | | | | 11 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immolute) | | 10,6 | 0,67 | 6,3 | 5 | 0 | CVPG | 10,8 | 0,20 | 20% | 8,64 | 13 | 5 | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 13,7 | 0,68 | 5,0 | 26 | 0 | CVPG | 13,6 | 0,11 | 20% | 10,8 | 16,4 | 26 | | | | | | | | 26 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 11,2 | 0,85 | 7,6 | 12 | 0 | CVPG | 11,5 | 0,29 | 20% | 9,2 | 13,8 | 12 | | | | | | | | 12 | | |
| Other | | | | | 1 | 0 | | | | | | | 0 | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2/25 | | | | | | | | |
| (305) Testosterone | | | | | 99 | | | | | | | 97 | 94 | 97% | | | | | | | 99 | 91 | 92% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 5,45 | 0,49 | 9,0 | 99 | | | | | | | 97 | 95 | 98% | CRV | 5,433 | 0,077 | 30% | 3,8 | 7,07 | 99 | 93 | 94% |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 7,51 | 0,43 | 5,7 | 5 | 0 | CVPG | 7,22 | 0,38 | 22% | 5,63 | 8,81 | 5 | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 5,27 | 0,35 | 6,6 | 28 | 0 | CVPG | 5,34 | 0,073 | 22% | 4,16 | 6,52 | 28 | | | | | | | | 28 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 5,52 | 0,28 | 5,1 | 14 | 0 | CVPG | 5,62 | 0,099 | 22% | 4,38 | 6,86 | 14 | | | | | | | | 14 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immolute) | | 4,44 | 0,57 | 13 | 6 | 0 | CVPG | 5,24 | 0,13 | 22% | 4,08 | 6,4 | 6 | | | | | | | | 6 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 5,58 | 0,31 | 5,5 | 31 | 0 | CVPG | 5,63 | 0,045 | 22% | 4,39 | 6,87 | 31 | | | | | | | | 31 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 5,28 | 0,45 | 8,6 | 12 | 0 | CVPG | 5,32 | 0,098 | 22% | 4,14 | 6,5 | 12 | | | | | | | | 12 | | |
| Other | | | | | 3 | 0 | | | | | | | 1 | | | | | | | | 3 | | |
| | | | | | | | | | | | | | | | 1x 2/25, 1x 3/15, 1x 4/40 | | | | | | | | |
| Sample B | | 4,25 | 0,32 | 7,6 | 99 | | | | | | | 97 | 95 | 98% | CRV | 4,615 | 0,054 | 30% | 3,23 | 6 | 99 | 96 | 97% |
| (3) FIA (FEIA, TRACE); (25) TOSOH | | 3,47 | 0,19 | 5,3 | 5 | 0 | CVPG | 3,39 | 0,20 | 22% | 2,64 | 4,14 | 5 | | | | | | | | 5 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 4,35 | 0,20 | 4,5 | 28 | 0 | CVPG | 4,36 | 0,055 | 22% | 3,4 | 5,32 | 28 | | | | | | | | 28 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 4,16 | 0,16 | 4,0 | 14 | 0 | CVPG | 4,24 | 0,062 | 22% | 3,3 | 5,18 | 14 | | | | | | | | 14 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immolute) | | 4,12 | 1,1 | 26 | 6 | 0 | CVPG | 4,46 | 0,10 | 22% | 3,47 | 5,45 | 6 | | | | | | | | 6 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 4,29 | 0,29 | 6,8 | 31 | 0 | CVPG | 4,32 | 0,037 | 22% | 3,36 | 5,28 | 31 | | | | | | | | 31 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 4,30 | 0,25 | 5,7 | 12 | 0 | CVPG | 4,25 | 0,071 | 22% | 3,31 | 5,19 | 12 | | | | | | | | 12 | | |
| Other | | | | | 3 | 0 | | | | | | | 1 | | | | | | | | 3 | | |
| | | | | | | | | | | | | | | | 1x 2/25, 1x 3/15, 1x 4/40 | | | | | | | | |

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

EQA round: E12/20 - Hormones 1

Deadline: 05.05.2020

| Test | [unit] | Comparability | | | | | Traceability | | | | | | | | | | | | | | | | |
|---|----------|---------------|------|--------|------------------|------------------|--------------|-----------------|------------------|------|------|------------------|------------------|------------------|----------------------------|-----------------|------------------|-------|------|------------------|------------------|------------------|------|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | AV | U _{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| (306) 17-OH-progesterone | | | | | 14 | | | | | | | 13 | 13 | 100% | | | | | | | 14 | 14 | 100% |
| Samples and groups | [nmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 7,02 | 0,65 | 9,2 | 14 | | | | | | | 13 | 13 | 100% | CRV | 7,113 | 0,071 | 44% | 3,98 | 10,3 | 14 | 14 | 100% |
| (1) RIA (IRMA); (36) Immunotech | | 7,33 | 1,4 | 19 | 8 | 0 | CVPG | 6,74 | 0,49 | 33% | 4,51 | 8,97 | 8 | | | | | | | | 8 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | | 7,14 | 0,50 | 7,0 | 5 | 0 | CVPG | 7,28 | 0,24 | 33% | 4,87 | 9,69 | 5 | | | | | | | | 5 | | |
| Other | | | | | 1 | 0 | | | | | | | 0 | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2/999 | | | | | | | | |
| Sample B | | 4,32 | 0,66 | 15 | 14 | | | | | | | 13 | 13 | 100% | CRV | 3,219 | 0,032±2,641 | 0,579 | 5,86 | | 14 | 14 | 100% |
| (1) RIA (IRMA); (36) Immunotech | | 3,84 | 0,54 | 14 | 8 | 0 | CVPG | 3,81 | 0,18 ±1,98 | 1,83 | 5,79 | 8 | | | | | | | | | 8 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems | | 4,73 | 0,11 | 2,4 | 5 | 0 | CVPG | 4,85 | 0,20 ±1,98 | 2,87 | 6,83 | 5 | | | | | | | | | 5 | | |
| Other | | | | | 1 | 0 | | | | | | 0 | | | | | | | | | 1 | | |
| | | | | | | | | | | | | | | | 1x 2/999 | | | | | | | | |
| (307) DHEA-S | | | | | 43 | | | | | | | 42 | 41 | 98% | | | | | | | 0 | | |
| Samples and groups | [µmol/L] | | | | | | | | | | | | | | | | | | | | | | |
| Sample A | | 13,6 | 1,8 | 13 | 43 | | | | | | | 42 | 41 | 98% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 13,5 | 0,78 | 5,8 | 11 | 0 | CVPG | 13,2 | 0,20 | 21% | 10,4 | 16 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 12,3 | 0,22 | 1,7 | 5 | 0 | CVPG | 11,8 | 0,43 | 21% | 9,32 | 14,3 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 14,7 | 0,84 | 5,7 | 15 | 0 | CVPG | 14,1 | 0,15 | 21% | 11,1 | 17,1 | 15 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 11,3 | 0,96 | 8,6 | 6 | 0 | CVPG | 10,8 | 0,28 | 21% | 8,53 | 13,1 | 6 | | | | | | | | | | |
| Other | | | | | 6 | 0 | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 2x 1/218, 1x 3/25, 3x 4/29 | | | | | | | | |
| Sample B | | 6,05 | 0,70 | 12 | 43 | | | | | | | 42 | 42 | 100% | | | | | | | 0 | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott | | 6,03 | 0,21 | 3,6 | 11 | 0 | CVPG | 5,92 | 0,089 | 21% | 4,67 | 7,17 | 11 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter | | 6,00 | 0,36 | 6,1 | 5 | 0 | CVPG | 5,58 | 0,24 | 21% | 4,4 | 6,76 | 5 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche | | 6,61 | 0,35 | 5,3 | 15 | 0 | CVPG | 6,35 | 0,068 | 21% | 5,01 | 7,69 | 15 | | | | | | | | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens | | 5,24 | 0,39 | 7,5 | 6 | 0 | CVPG | 5,13 | 0,14 | 21% | 4,05 | 6,21 | 6 | | | | | | | | | | |
| Other | | | | | 6 | 0 | | | | | | 5 | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 2x 1/218, 1x 3/25, 3x 4/29 | | | | | | | | |

st_kn_np

End of report

Printed: 21.05.2020